Mixed Bag For Biopharma Funding In 2025: Thoughts From J.P. Morgan, Biotech Showcase

Macro Issues A Challenge, Biotech Fundamentals Positive

 
• By Mandy Jackson

Scrip used the J.P. Morgan Healthcare Conference and Biotech Showcase to speak with investors and gauge the health of the capital markets this year.

Biopharma valuations have leveled off from past declines, but struggle to stay positive (Shutterstock)

More from Financing

More from Scrip